![](/img/cover-not-exists.png)
Cost-effectiveness analysis of the SP142 versus 22C3 PD-L1 assays in the treatment of atezolizumab plus nab -paclitaxel for patients with advanced triple negative breast cancer in the Brazilian private healthcare system
Shimabukuro Ho, Rodrigo, Mioti Sebastião, Mariana, Venezian de Carvalho, João Paulo, Neves, Tomás, Nussbaum, MichaJournal:
Journal of Medical Economics
DOI:
10.1080/13696998.2020.1821039
Date:
September, 2020
File:
PDF, 883 KB
2020